Amgen’s first quarter earnings beat analysts’ estimates, while revenue growth remained flattish.
The biotech company’s first quarter adjusted earnings came in at $3.56 per share, compared to analysts’ estimates of $3.48. Unadjusted earnings per share of $3.18 fell from the year-ago quarter’s $3.25.
While revenue remained the same at $5.6 billion, expenses in the quarter increased +9% year-over-year to $3.1 billion.
The company’s revenue from Blincyto, its first bi-specific antibody for the treatment of cancer, surged +41% year-over-year to $69 million. Sales of its highest selling drug, Enbrel, rose +4% to $1.15 billion.
Research & Development (R&D) expenses increased +16% largely towards bolstering the company’s oncology programs, as indicated by Amgen.
For the full-year 2019, Amgen projects a revenue range of $22 billion and $22.9 billion. It lowered the top end of the range of its earnings per share forecast by $0.02, now expecting between $11.68 and $12.73 per share.
Amgen shares fell -2.2% on Wednesday.
AMGN saw its Momentum Indicator move above the 0 level on March 21, 2024. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 81 similar instances where the indicator turned positive. In of the 81 cases, the stock moved higher in the following days. The odds of a move higher are at .
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where AMGN's RSI Oscillator exited the oversold zone, of 32 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for AMGN just turned positive on March 20, 2024. Looking at past instances where AMGN's MACD turned positive, the stock continued to rise in of 44 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where AMGN advanced for three days, in of 296 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AMGN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
AMGN broke above its upper Bollinger Band on March 27, 2024. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for AMGN entered a downward trend on March 26, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 71, placing this stock better than average.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: AMGN's P/B Ratio (24.631) is slightly higher than the industry average of (5.792). P/E Ratio (22.923) is within average values for comparable stocks, (49.793). Projected Growth (PEG Ratio) (2.555) is also within normal values, averaging (3.057). Dividend Yield (0.030) settles around the average of (0.029) among similar stocks. P/S Ratio (5.464) is also within normal values, averaging (3.723).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. AMGN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a manufacturer of human therapeutic products based on cellular biology
Industry PharmaceuticalsMajor